P590: PRELIMINARY SAFETY AND EFFICACY OF BGB-11417, A POTENT AND SELECTIVE B-CELL LYMPHOMA 2 (BCL2) INHIBITOR, IN PATIENTS (PTS) WITH ACUTE MYELOID LEUKEMIA (AML)

• J. Shortt,
• S. Y. Tan,
• P. Cannell,
• T. F. Ng,
• C. Y. Fong,
• S. Ramanathan,
• R. Rajagopal,
• S. Leitch,
• R. Gasiorowski,
• C. Grove,
• D. Lenton,
• P. Tan,
• C. DiNardo,
• M. T. Ling,
• S. Cheng,
• Y. Liu,
• M. Co,
• W. Y. Chan,
• D. Simpson,
• A. H. Wei

Affiliations

J. Shortt

1 School of Clinical Sciences, Monash University and Monash Health, Clayton

S. Y. Tan

2 St Vincent’s Hospital Melbourne, Fitzroy, Victoria

P. Cannell

3 Fiona Stanley Hospital, Murdoch, Western Australia

T. F. Ng

4 Gold Coast University Hospital, Southport, Queensland

C. Y. Fong

5 Austin Health, Heidelberg, Victoria

S. Ramanathan

6 The Saint George Hospital-Kogarah, Kogarah, New South Wales, Australia

R. Rajagopal

7 Middlemore Hospital

S. Leitch

8 North Shore Hospital, Auckland, New Zealand

R. Gasiorowski

9 Concord Repatriation General Hospital, Concord West, New South Wales

C. Grove

10 Linear Clinical Research & Sir Charles Gairdner Hospital, Nedlands, Western Australia

D. Lenton

11 Orange Health Service (Central West Cancer Care Centre), Orange, New South Wales

P. Tan

12 One Clinical Research, Nedlands, Western Australia, Australia

C. DiNardo

13 University of Texas MD Anderson Cancer Center, Houston, TX

M. T. Ling

14 BeiGene (Shanghai) Co., Ltd., Shanghai, China and BeiGene USA, Inc., San Mateo, CA, United States of America

S. Cheng

14 BeiGene (Shanghai) Co., Ltd., Shanghai, China and BeiGene USA, Inc., San Mateo, CA, United States of America

Y. Liu

14 BeiGene (Shanghai) Co., Ltd., Shanghai, China and BeiGene USA, Inc., San Mateo, CA, United States of America

M. Co

14 BeiGene (Shanghai) Co., Ltd., Shanghai, China and BeiGene USA, Inc., San Mateo, CA, United States of America

W. Y. Chan

14 BeiGene (Shanghai) Co., Ltd., Shanghai, China and BeiGene USA, Inc., San Mateo, CA, United States of America

D. Simpson

14 BeiGene (Shanghai) Co., Ltd., Shanghai, China and BeiGene USA, Inc., San Mateo, CA, United States of America

A. H. Wei

12 One Clinical Research, Nedlands, Western Australia, Australia